| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 282 | 2022 |
| A comprehensive comparison of early-onset and average-onset colorectal cancers A Cercek, WK Chatila, R Yaeger, H Walch, GDS Fernandes, A Krishnan, ... JNCI: Journal of the National Cancer Institute 113 (12), 1683-1692, 2021 | 93 | 2021 |
| Genetic determinants of outcome in intrahepatic cholangiocarcinoma T Boerner, E Drill, LM Pak, B Nguyen, CS Sigel, A Doussot, P Shin, ... Hepatology 74 (3), 1429-1444, 2021 | 88 | 2021 |
| Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer WK Chatila, JK Kim, H Walch, MR Marco, CT Chen, F Wu, DM Omer, ... Nature medicine 28 (8), 1646-1655, 2022 | 52 | 2022 |
| Specific mutations in APC, but not alterations in DNA damage response, associate with outcomes of patients with metastatic colorectal cancer S Mondaca, H Walch, S Nandakumar, WK Chatila, N Schultz, R Yaeger Gastroenterology 159 (5), 1975-1978. e4, 2020 | 28 | 2020 |
| Molecular classification of appendiceal adenocarcinoma MB Foote, H Walch, W Chatila, E Vakiani, C Chandler, F Steinruecke, ... Journal of Clinical Oncology 41 (8), 1553-1564, 2023 | 16 | 2023 |
| EGFR Amplification in Metastatic Colorectal Cancer G Randon, R Yaeger, JF Hechtman, P Manca, G Fucà, H Walch, J Lee, ... JNCI: Journal of the National Cancer Institute 113 (11), 1561-1569, 2021 | 16 | 2021 |
| Tumor mutational burden and mismatch repair deficiency discordance as a mechanism of immunotherapy resistance AA Bielska, WK Chatila, H Walch, N Schultz, ZK Stadler, J Shia, ... Journal of the National Comprehensive Cancer Network 19 (2), 130-133, 2021 | 15 | 2021 |
| Survival of locally advanced msi-high gastric cancer patients treated with perioperative chemotherapy: a retrospective cohort study EL Vos, SB Maron, RW Krell, M Nakauchi, M Fiasconaro, M Capanu, ... Annals of surgery 277 (5), 798-805, 2023 | 14 | 2023 |
| Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers WK Chatila, H Walch, JF Hechtman, SM Moyer, V Sgambati, DM Faleck, ... Nature communications 14 (1), 110, 2023 | 11 | 2023 |
| Epidermal growth factor receptor inhibition in epidermal growth factor receptor–amplified gastroesophageal cancer: retrospective global experience SB Maron, S Moya, F Morano, MJ Emmett, JF Chou, S Sabwa, H Walch, ... Journal of Clinical Oncology 40 (22), 2458, 2022 | 10 | 2022 |
| Defining and targeting Esophagogastric Cancer genomic subsets with patient-derived xenografts RH Moy, HS Walch, M Mattar, WK Chatila, D Molena, VE Strong, LH Tang, ... JCO Precision Oncology 6, e2100242, 2022 | 9 | 2022 |
| The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival. EL Vos, SB Maron, RW Krell, M Nakauchi, M Fiasconaro, HS Walch, ... Journal of Clinical Oncology 39 (3_suppl), 244-244, 2021 | 9 | 2021 |
| Next-generation sequencing of 487 esophageal adenocarcinomas reveals independently prognostic genomic driver alterations and pathways S Sihag, SC Nussenzweig, HS Walch, M Hsu, KS Tan, F Sanchez-Vega, ... Clinical Cancer Research 27 (12), 3491-3498, 2021 | 8 | 2021 |
| Genomic predictors of recurrence patterns after complete resection of colorectal liver metastases and adjuvant hepatic artery infusion chemotherapy RR Narayan, J Datta, DA Goldman, VG Aveson, HS Walch, ... Annals of surgical oncology 29 (12), 7579-7588, 2022 | 7 | 2022 |
| The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma S Sihag, SC Nussenzweig, HS Walch, M Hsu, KS Tan, S De La Torre, ... Clinical Cancer Research 28 (12), 2669-2678, 2022 | 7 | 2022 |
| Association of genomic profiles and survival in early onset and screening‐age colorectal cancer patients with liver metastases resected over 15 years RR Narayan, VG Aveson, JF Chou, HS Walch, F Sanchez‐Vega, ... Journal of surgical oncology 125 (5), 880-888, 2022 | 7 | 2022 |
| Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination JM Schvartzman, G Forsyth, H Walch, W Chatila, A Taglialatela, BJ Lee, ... Molecular Cell 83 (13), 2347-2356. e8, 2023 | 6 | 2023 |
| Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma BL Ecker, AJ Tao, QP Janssen, HS Walch, CM Court, VP Balachandran, ... Clinical Cancer Research 29 (7), 1368-1374, 2023 | 6 | 2023 |
| Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results. D Cowzer, AJC Wu, S Sihag, HS Walch, BJ Park, DR Jones, P Gu, ... Journal of Clinical Oncology 40 (16_suppl), 4029-4029, 2022 | 6 | 2022 |
